An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- PMID: 26177183
- DOI: 10.1164/rccm.201506-1063ST
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
Erratum in
-
Erratum: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.Am J Respir Crit Care Med. 2015 Sep 1;192(5):644. doi: 10.1164/rccm.1925erratum. Am J Respir Crit Care Med. 2015. PMID: 26325160 No abstract available.
Abstract
Background: This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.
Methods: Systematic reviews and, when appropriate, meta-analyses were performed to summarize all available evidence pertinent to our questions. The evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and then discussed by a multidisciplinary panel. Predetermined conflict-of-interest management strategies were applied, and recommendations were formulated, written, and graded exclusively by the nonconflicted panelists.
Results: After considering the confidence in effect estimates, the importance of outcomes studied, desirable and undesirable consequences of treatment, cost, feasibility, acceptability of the intervention, and implications to health equity, recommendations were made for or against specific treatment interventions.
Conclusions: The panel formulated and provided the rationale for recommendations in favor of or against treatment interventions for idiopathic pulmonary fibrosis.
Comment in
-
An Important Step Forward, but Still a Way to Go.Am J Respir Crit Care Med. 2016 Feb 1;193(3):340-1. doi: 10.1164/rccm.201509-1763LE. Am J Respir Crit Care Med. 2016. PMID: 26829426 No abstract available.
-
Idiopathic Pulmonary Fibrosis and Prothrombotic State.Am J Respir Crit Care Med. 2016 Feb 1;193(3):341-2. doi: 10.1164/rccm.201509-1835LE. Am J Respir Crit Care Med. 2016. PMID: 26829427 No abstract available.
-
Reply to "An Important Step Forward, but Still a Way to Go".Am J Respir Crit Care Med. 2016 Feb 1;193(3):342. doi: 10.1164/rccm.201510-2010LE. Am J Respir Crit Care Med. 2016. PMID: 26829428 No abstract available.
-
Reply to "An Important Step Forward, but Still a Way to Go" and "Idiopathic Pulmonary Fibrosis and Prothrombotic State".Am J Respir Crit Care Med. 2016 Feb 1;193(3):343. doi: 10.1164/rccm.201510-2049LE. Am J Respir Crit Care Med. 2016. PMID: 26829429 No abstract available.
-
Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2016 Apr 1;193(7):810-1. doi: 10.1164/rccm.201511-2267LE. Am J Respir Crit Care Med. 2016. PMID: 27035785 No abstract available.
-
Reply: Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2016 Apr 1;193(7):811. doi: 10.1164/rccm.201601-0078LE. Am J Respir Crit Care Med. 2016. PMID: 27035786 No abstract available.
-
Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2017 Jan 15;195(2):269-270. doi: 10.1164/rccm.201605-1074LE. Am J Respir Crit Care Med. 2017. PMID: 28084819 No abstract available.
-
Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?Am J Respir Crit Care Med. 2017 Jan 15;195(2):271. doi: 10.1164/rccm.201608-1610LE. Am J Respir Crit Care Med. 2017. PMID: 28084827 No abstract available.
Similar articles
-
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST. Am J Respir Crit Care Med. 2018. PMID: 30168753
-
Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline.Am J Respir Crit Care Med. 2018 Jun 15;197(12):e24-e39. doi: 10.1164/rccm.201805-0819ST. Am J Respir Crit Care Med. 2018. PMID: 29905515 Free PMC article.
-
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST. Am J Respir Crit Care Med. 2022. PMID: 35486072 Free PMC article.
-
Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis: Joint Consensus of Sociedade Portuguesa de Pneumologia, Sociedade Portuguesa de Radiologia e Medicina Nuclear e Sociedade Portuguesa de Anatomia Patológica.Rev Port Pneumol (2006). 2016 Mar-Apr;22(2):112-22. doi: 10.1016/j.rppnen.2016.01.003. Epub 2016 Feb 20. Rev Port Pneumol (2006). 2016. PMID: 26906287
-
Review of IPF diagnosis and management recommendations in Europe.Sarcoidosis Vasc Diffuse Lung Dis. 2013 Dec 17;30(4):249-61. Sarcoidosis Vasc Diffuse Lung Dis. 2013. PMID: 24351616 Review.
Cited by
-
The link between smoking, emphysema, and fibrosis: A retrospective cohort study.Tob Induc Dis. 2024 Jul 19;22. doi: 10.18332/tid/190689. eCollection 2024. Tob Induc Dis. 2024. PMID: 39034966 Free PMC article.
-
Impact of Controlling Nutritional Status Score on Mortality in Elderly Patients with Idiopathic Pulmonary Fibrosis.J Clin Med. 2024 May 10;13(10):2825. doi: 10.3390/jcm13102825. J Clin Med. 2024. PMID: 38792367 Free PMC article.
-
A study on the prevalence and prognosis of progressive pulmonary fibrosis: A retrospective observational study.Medicine (Baltimore). 2024 May 17;103(20):e38226. doi: 10.1097/MD.0000000000038226. Medicine (Baltimore). 2024. PMID: 38758869 Free PMC article.
-
Exploring the efficacy and molecular mechanism of Danhong injection comprehensively in the treatment of idiopathic pulmonary fibrosis by combining meta-analysis, network pharmacology, and molecular docking methods.Medicine (Baltimore). 2024 May 10;103(19):e38133. doi: 10.1097/MD.0000000000038133. Medicine (Baltimore). 2024. PMID: 38728523 Free PMC article.
-
Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor.Nano Today. 2024 Feb;54:102058. doi: 10.1016/j.nantod.2023.102058. Epub 2023 Nov 15. Nano Today. 2024. PMID: 38681872
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical